PATENT CLAIM ANALYSIS

Application Number: 15771941
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "037000"]

Abstract:
This invention concerns the use of mefloquine in relation to  Mycobacterium tuberculosis . This invention also concerns the combination of mefloquine with drugs used in first and second choice treatment of tuberculosis, achieving a reduction in the treatment period of tuberculosis (TB) and the treatment of multi-drug resistant tuberculosis (MDR-TB).

Claim (Index 6):
Method for treating tuberculosis in a mammal that comprises administering, to said mammal in need of same, an effective quantity of mefloquine in combination with at least one, and a maximum of 3, anti-tuberculosis drugs, where the anti-tuberculosis drugs are selected from a group consisting of isoniazid, pyrazinamide, rifampicin, ethambutol, streptomycin, ethionamide, aminosalicylic acid, cycloserine, amikacin, Kanamycin, capreomycin, linezolid, gatifloxacin, moxifloxacin, sparfloxacin, ofloxacin, ciprofloxacin and levofloxacin.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.64706
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['10844992', '15546680', '15409911', '14112720', '14816377']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8019366689304146
- 35 USC 102 Novelty (BERT): 0.5068185919880794
- Combined Prediction Score: 0.7724248612361811
- Mean Citation Score: 244.150188
- Max Citation Score: 269.5635
- Similarity Product: 188.05744512185453

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test